Clinical Trials on Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type in United Kingdom

Total 491 results

M.D. Anderson Cancer Center

Recruiting

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type

United States
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Human Papillomavirus Infection | Stage IVB Cervical Cancer AJCC v6 and v7

United States, Canada
Queen Mary University of London
AstraZeneca; Vall d'Hebron Institute of Oncology

Active, not recruiting

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)

Renal Clear Cell Carcinoma | Renal Papillary Cell Carcinoma

United Kingdom
M.D. Anderson Cancer Center
GSK Pharma; Lixte

Recruiting

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Ovarian Clear Cell Carcinoma

United States
University of Derby

Unknown

Investigation Into the Infectivity Levels of Human Papilloma Virus (HPV) in Tonsillar Tissue

Human Papillomavirus, Palatine Tonsil

United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...

United States
University of Oklahoma
ImmunoGen, Inc.

Withdrawn

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma

United States
Women's Cancer Care Associates, LLC

Completed

Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol

Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IIIC Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer

United States, Canada
Nuvectis Pharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Recruiting

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Ovarian Cancer | Ovarian Endometrioid Adenocarcinoma | Advanced Solid Tumor | Ovarian Clear Cell Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Clear Cell Tumor | Ovarian Endometrioid Tumor | ARID1A Gene Mutation

United States, United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
NHS Greater Glasgow and Clyde
Boehringer Ingelheim; Cancer Research UK; European Organisation for Research... and other collaborators

Unknown

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC)

Ovarian Clear Cell Carcinoma | Endometrial Clear Cell Carcinoma

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Cervical Small Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Endometrial Clear Cell Carcinoma | Stage III Endometrial Carcinoma | Cervical... and other conditions

United States, Korea, Republic of, Japan, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
University of Washington
National Cancer Institute (NCI)

Completed

Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening

Cervical Carcinoma | Human Papillomavirus Infection | Health Status Unknown | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical Cancer | Atypical Squamous Cell of Undetermined Significance | Low Grade Cervical Squamous Intraepithelial Neoplasia

United States
Elizabeth K. Lee MD
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Gynecologic Cancer | Ovarian Clear Cell Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma

United States
TScan Therapeutics, Inc.
Washington University School of Medicine

Withdrawn

Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors

Renal Clear Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Advanced Cervical Adenocarcinoma | Human Papillomavirus-Related Cervical Squamous Cell Carcinoma | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma | Stage III Cervical Cancer AJCC v8 | Stage IIIA... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
University of Miami
Cigna Foundation

Completed

Research in Ethno-Medicine and Education (REMED) (REMED)

Cervical Cancer | HPV | Human Papillomavirus Infection | Human Papilloma Virus

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Queen Mary University of London
AstraZeneca; Cancer Research UK

Terminated

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (ZEBRA)

Metastatic Clear Cell Renal Carcinoma

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Terminated

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Celldex Therapeutics

Terminated

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Kidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell Carcinoma

United States
Queen Mary University of London
Novartis

Completed

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer (DEVELOP)

Metastatic Clear Cell Renal Cancer

United Kingdom
University of Edinburgh

Recruiting

The Role of Circulating Tumour DNA in Head and Neck Cancer

Oropharyngeal Squamous Cell Carcinoma | Human Papillomavirus (HPV)

United Kingdom
National Cancer Institute (NCI)
NRG Oncology

Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Recurrent Uterine Corpus Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Active, not recruiting

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Breast Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Cancer | Uterine Corpus Carcinosarcoma

United States
Mayo Clinic

Recruiting

Prospective Assessment of HPV Associated Anogenital Pathology in Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma, PAP-OP Study

Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma

United States
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Human Papillomavirus Infection

United States
Active Biotech AB

Completed

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Renal Cell Carcinoma | Pancreatic Cancer | Non-Small-Cell Lung Carcinoma

United States, Norway, United Kingdom
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)

Human Papillomavirus-Related Carcinoma | Human Papillomavirus Positive Oropharyngeal Carcinoma | Human Papillomavirus Positive Cervical Carcinoma | Human Papillomavirus Positive Anal Carcinoma | Human Papillomavirus Positive Vulvar Carcinoma | Human Papillomavirus Positive Penile Carcinoma

United States
Amgen

Completed

AMG 172 First in Human Study in Patients With Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell Adenocarcinoma

France, United States, Germany
Pamela Munster
Novartis

Withdrawn

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Solid Tumors, Adult | HPV-Related Squamous Cell Carcinoma | Human Papillomavirus-Related Carcinoma | PIK3CA Mutation-Related Tumors | PIK3CA Mutation | Human Papillomavirus-Related Squamous Cell Carcinoma

United States
Regenstrief Institute, Inc.
Merck Sharp & Dohme LLC

Completed

Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine

Cervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6

United States
Guru Sonpavde
Pfizer; Hoosier Cancer Research Network

Withdrawn

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Kidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Comparison Study of Two Community Outreach-Based Approaches to Increase Participation of Women Living in the Mississippi Delta in Cervical Cancer Screening

Cervical Intraepithelial Neoplasia | Human Papillomavirus

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
Gynecologic Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma | Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Active, not recruiting

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Extra Renal Origin | Clear Cell Adenocarcinoma

United States
Imperial College London
North Eastern German Society of Gynaecological Oncology; Takeda Pharmaceuticals...

Active, not recruiting

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (DICE)

Ovarian Neoplasms | Fallopian Tube Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Carcinoma | Ovarian Carcinosarcoma

United Kingdom, Germany
National Cancer Institute (NCI)

Terminated

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Human Papillomavirus | HPV-16 | High Grade Squamous Intraepithelial Lesion

United States
Queen Mary University of London

Unknown

A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther) (Panther)

Metastatic Clear Cell Renal Cancer

United Kingdom

Clinical Trials on Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations